Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.73 - $4.92 $2.2 Million - $3.96 Million
804,281 Added 28.29%
3,647,430 $8.54 Million
Q2 2022

Aug 05, 2022

BUY
$2.8 - $7.67 $6.35 Million - $17.4 Million
2,268,814 Added 395.03%
2,843,149 $8.62 Million
Q1 2022

May 16, 2022

BUY
$6.01 - $8.54 $3.45 Million - $4.9 Million
574,335 New
574,335 $3.9 Million

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.